Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets

European Journal of Neuroscience

Volumn 21, Issue 12, 2005, Pages 3240-3250

  Hurley, Michael J ^a   Jackson, M J ^a   Smith, L A ^a   Rose, S ^a   Jenner, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Callithrix jacchus; Dyskinesia; NMDA receptors; Parkinson's disease; Scaffold proteins

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROFILAMENT PROTEIN; POSTSYNAPTIC DENSITY PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 93; POSTSYNAPTIC DENSITY PROTEIN 95; RECEPTOR SUBUNIT; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; GLOBUS PALLIDUS; HIPPOCAMPUS; MARMOSET; MOTOR CORTEX; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BLOTTING, WESTERN; BRAIN; CALLITHRIX; DIAGNOSTIC IMAGING; DYSKINESIA, DRUG-INDUCED; IMMUNORADIOMETRIC ASSAY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEVODOPA; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; NEUROFILAMENT PROTEINS; PROTEIN SUBUNITS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; TYROSINE 3-MONOOXYGENASE;

EID: 21844449693     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2005.04169.x     Document Type: Article

References (52)

1. Albin, R.L., Young, A.B. & Penney, J.B. (1989) The functional anatomy of basal ganglia disorders. TINS, 12, 366-375.
2. Andersson, O., Stenqvist, A., Attersand, A. & von Euler, G. (2001) Nucleotide sequence, genomic organization and chromasomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B. Genomics, 78, 178-184.
3. Bezard, E., Crossman, A.R., Gross, C.E. & Brotchie, J.M. (2001) Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB, 15, 1092-1094.
4. Blanchet, P.J., Konitsiotis, S. & Chase, T.N. (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord., 13, 798-802.
5. Blanchet, P.J., Konitsiotis, S., Whittemore, E.R., Zhou, Z.L., Woodward, R.M. & Chase, T.N. (1999) Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in Levodopa-treated 1-Methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther., 290, 1034-1040.
6. Calabresi, P., Giacomini, P., Centonze, D. & Bernardi, G. (2000) Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann. Neurol., 47, S60-S68.
7. A receptors in the stiatopallidal complex. Brain Res., 680, 43-52.
8. Calon, F., Rajput, A.H., Hornykiewicz, O., Bedard, P.J. & Di Paolo, T. (2003) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis., 14, 404-416.
9. Cannizzaro, C., Tel, B.C., Rose, S., Zeng, B.Y. & Jenner, P. (2003) Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Mol. Brain Res., 110, 169-176.
10. Carroll, R.C. & Zukin, R.S. (2002) NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity. TINS, 25, 571-577.
11. Cenci, M.A., Lee, C.S. & Björklund, A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694-2706.
12. Cenci, M.A., Tranberg, A., Andersson, M. & Hilbertson, A. (1999) Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-DOPA treatment. Neuroscience, 94, 515-527.
13. Chase, T.N. (2004) Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Related Disorders, 10, 305-313.
14. Clinton, S.M. & Meador-Woodruff, J.H. (2004) Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology, 29, 1353-1362.
15. DeLong, M.R. (1990) Primate models of movement disorders of basal ganglia. TINS, 13, 281-285.
16. Di Monte, D.A., McCormack, A., Petzinger, G., Janson, A.M., Quik, M. & Langston, W.J. (2000) Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord., 15, 459-466.
17. Dunah, A.W., Wang, Y., Yasuda, R.P., Kameyama, K., Huganir, R.L., Wolfe, B.B. & Standaert, D.G. (2000) Alterations in subunit expression, composition and phosphorylation of striatal N-methyl-D-Aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol., 57, 342-352.
18. Ehlers, M.D., Fung, E.T., O'Brien, R.J. & Huganir, R.L. (1998) Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J. Neurosci., 18, 720-730.
19. Escola, L., Michelet, Th, Macia, F., Guehl, D., Bioulac, B. & Burbaud, P. (2003) Disruption of information processing in the supplementary motor area of the MPTP-treated monkey. A clue to the pathophysiology of akinesia? Brain, 126, 95-114.
20. Fukaya, M., & Watanabe, M. (2000) Improved immunohistochemical detection of postsynaptically located PSD-95/SAP90 protein family by protease section pretreatment: a study in adult mouse. J. Comp. Neurol., 426, 572-586.
21. Hallett, P.J. & Standaert, D.G. (2004) Rationale for the use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther., 102, 155-174.
22. Henry, B., Duty, S., Fox, S.H., Crossman, A.R. & Brotchie, J.M. (2003) Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol., 183, 458-468.
23. Hollman, M. & Heinemann, S. (1994) Cloned glutamate receptors. Annu. Rev. Neurosci., 17, 31-108.
24. Hurley, M.J., Gerard, D.J., Jauniaux, E., Stern, G.M., Uchida, K. & Bradford, H.F. (2001) Cultured human foetal cerebral cortex, transfected with tyrosine hydroxylase cDNA, as a source of neural transplant material. J. Neural Transm., 108, 781-792.
25. Jenner, P. (2000) Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J. Neurol., 247, 1143-1150.
26. Kennedy, M.B. (1997) The postsynaptic density at glutamatergic synapses. TINS, 20, 264-268.
27. Kennedy, M.B. (1998) Signal transduction molecules at the glutaminergic postsynaptic membrane. Brain Res. Rev., 26, 243-257.
28. Levy, R., Herrero, M.T., Ruberg, M., Villares, J., Faucheux, B., Guridi, J., Guillen, J., Luquin, M.R., Javoy-Agid, F., Obeso, J.A. & Hirsch, E.C. (1995) Effects of nigrostriatal denervation and 1-dopa therapy on the GABAergic neurones in the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA. Eur. J. Neurosci., 7, 1199-1209.
29. Löschmann, P.A., De Groote, C., Smith, L.A., Wullner, U., Fischer, G., Kemp, J.A., Jenner, P. & Klockgether, T. (2004) Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp. Neurol., 187, 86-93.
30. Marsden, C.D. (1982) The mysterious motor function of the basal ganglia: The Robert Wartenberg Lecture. Neurology, 32, 514-539.
31. Metman, L.V., Del Potto, P., Van der Munckhof, P., Fang, J., Mouradian, M.M. & Chase, T.N. (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology, 50, 1323-1326.
32. Mueller, H.T., Haroutunian, V., Davis, K.L. & Meador-Woodruff, J.H. (2004) Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Mol. Brain Res., 121, 60-69.
33. Nada, S., Shima, T., Yanai, H., Husi, H., Grant, S.G.N., Okada, M. & Akiyama, T. (2003) Identification of PSD-93 as a substrate for the Src family tyrosine kinase Fyn. J. Biol. Chem., 278, 47610-47621.
34. Nicoll, R.A. & Malenka, R.C. (1995) Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature, 377, 115-118.
35. O'Carroll, C.M. & Morris, R.G.M. (2004) Heterosynaptic co-activation of glutamatergic and dopaminergic afferents is required to induce persistent long-term potentiation. Neuropharmacology, 47, 324-332.
36. Obeso, J.A., Rodriguez-Oroz, M.C., Rod, M., Lanciego, J.L., Artieda, J., Gonzalo, N. & Olanow, C. W. (2000) Pathophysiology of the basal ganglia in Parkinson's disease. TINS, 23, S8-S19.
37. Oh, J.D., Chartisathian, K., Ahmed, S.M. & Chase, T.N. (2003) Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats. J. Neurosci. Res., 72, 768-780.
38. Oh, J.D., Russell, D., Vaughan, C.L. & Chase, T.N. (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res., 813, 150-159.
39. Oh, J.D., Vaughan, C.L. & Chase, T.N. (1999) Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res., 821, 433-442.
40. Papa, S.M., Boldry, R.C., Engber, T.M., Kask, A.M. & Chase, T.N. (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res., 701, 13-18.
41. Pearce, R.K., Jackson, M.J., Smith, L.A., Jenner, P. & Marsden, C.D. (1995) Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset. Mov. Disord., 10, 731-740.
42. Picconi, B., Centonze, D., Hakansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M.A. & Calabresi, P. (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature Neurosci., 6, 501-506.
43. Rascol, O., Sabatini, U., Brefel, C., Fabre, N., Rai, S., Senard, J.M., Celsis, P., Viallard, G., Montastruc, J.L. & Chollet, F. (1998) Cortical motor overactivation in parkinsonian patients with L-DOPA-induced peak-dose dyskinesia. Brain, 121, 527-533.
44. Scannevin, R.H. & Huganir, R.L. (2000) Postsynaptic organization and regulation of excitatory synapses. Nature Rev. Neurosci., 1, 133-141.
45. Schrag, A. & Quinn, N. (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community based study. Brain, 123, 2297-2305.
46. Sheng, M. & Pak, D.T. (1999) Glutamate receptor anchoring proteins and the molecular organization of excitatory synapses. Neuroscience, 868, 483-493.
47. Stephan, H., Baron, G. & Schwerdtfeger, W. (1980) The Brain of the Common Marmoset: Callithrix Jacchus. Springer-Verlag, Berlin, New York.
48. Tanji, J. (1994) The supplementary motor area in the cerebral cortex. Neurosci. Res., 19, 251-268.
49. Tanji, J. (2001) Sequential organization of multiple movements: Involvement of cortical motor areas. Annu. Rev. Neurosci., 24, 631-651.
50. Wessell, R.H., Ahmed, S.M., Menniti, F.S., Dunbar, G.L., Chase, T.N. & Oh, J.D. (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology, 47, 184-194.
51. Westin, J.E., Andersson, M., Lundblad, M. & Cenci, M.A. (2001) Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur. J. Neurosci., 14, 1171-1176.
52. Winkler, C., Kirik, D., Björklund, A. & Cenci, M.A. (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: Relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis., 10, 165-186.